Visible Results

In Trial 6, adolescent patients with moderate‑to‑severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT or placebo. Adolescents ≥60 kg received DUPIXENT 300 mg Q2W following a 600 mg loading dose, while adolescents <60 kg received 200 mg Q2W following a 400 mg loading dose. The primary endpoint was the change from baseline to Week 16 in the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2‑point improvement.1,2

Significant skin clearance was demonstrated in adolescents (primary endpoint; P<0.001)1-3,a

Efficacy Results of DUPIXENT
at Week 16 (FAS)
DUPIXENT
(n=82)
PLACEBO
(n=85)
Achieved
clear or
almost‑
clear skin
(IGA 0 or 1)
24% 2%
  • a Responder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2‑points on a 0‑4 scale at Week 16 (primary efficacy outcome).

Visible Results in an Adolescent Patient

Adolescent patient achieved a 2-point improvement in IGA

Baseline:

IGA 4 (severe)

Week 16:

IGA 2 (mild)

Actual 12-year-old patient in the phase 3 adolescent DUPIXENT trial. Patient had a baseline IGA of 4 and EASI of 31. Individual results may vary.

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point
improvement from baseline1

  • This adolescent patient would not have met the primary endpoint in the clinical trials based on their IGA scores at Week 16
See Changes in Adults Not Achieving
IGA 0 or 1
  • BSA, body surface area.
Dosing and Administration Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
DUPIXENT MyWay Get access support and information
about benefits investigations,
prior authorizations, and Medical
Necessity and appeal letters.
Explore Access Resources
References:
  1. DUPIXENT Prescribing Information.
  2. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial [published online November 6, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.3336
  3. Data on file, Regeneron Pharmaceuticals, Inc.